The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1337-1343

  Preiss, D ^b   Sattar, N ^a,c   Harborne, L ^c   Norman, J ^c   Fleming, R ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; INSULIN; LEPTIN; LIPID; METFORMIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE ASSAY; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTI-OBESITY AGENTS; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; METFORMIN; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 49349084059     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01825.x     Document Type: Article

References (28)

1. Bacon BR, Farahvash MJ, Janney CG, Neuschwander Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994 2: 1103 9.
2. Sattar N, Scherbakova O, Ford I et al. West of Scotland coronary prevention study. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004 53: 2855 60.
3. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007 191: 235 40.
4. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 327: 951 5.
5. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005 90: 5711 6.
6. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 90: 1929 35.
7. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001 28: 99 109.
8. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007 5: 496 501.
9. Tiikkainen M, Bergholm R, Vehkavaara S et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 52: 701 7.
10. Westerbacka J, Cornér A, Tiikkainen M et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004 47: 1360 9.
11. Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007 96: 542 7.
12. Radetti G, Kleon W, Stuefer J, Pittschieler K. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr 2006 95: 833 7.
13. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005 83: 494 7.
14. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002 137: 1 10.
15. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005 42: 650 6.
16. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 2007 53: 686 92.
17. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005 90: 4593 8.
18. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004 19: 537 44.
19. Bugianesi E, Gentilcore F, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005 100: 1082 90.
20. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004 53: 2169 76.
21. Adams JM, Polson JW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986 293: 355 9.
22. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis. Manual of Laboratory Operations, Vol. 1. Bethesda, MD: DHEW Publications (NIH), 1975, 75.
23. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005 28: 2913 8.
24. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007 1: CD005166.
25. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006 332: 1485.
26. Legro RS, Barnhart HX, Schlaff WD et al. Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007 356: 551 66.
27. Sattar N, McConnachie A, Ford I et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007 56: 984 91.
28. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346: 393 403.